Drug
LU Aa24493
LU Aa24493: highest development phase Phase 2, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AA24493 NCT01016366 | Phase 2 | Friedreich's Ataxia |
Latest
No recent events.
Follow LU Aa24493 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.